

**Tchaikapharma High Quality Medicines Inc.**  
**Interim statement of Financial status**  
**as of 30 of June 2019**

	30.06.2019	31.12.2018
	BGN'000	BGN'000
<b>ASSETS</b>		
<b>Non-current assets</b>		
Property, plant and equipment	24 380	25 754
Intangible assets	2 936	2 871
Investment in minority interest	1	1
Trade receivables	4 968	4 968
<b>Total non-current assets</b>	<b>32 285</b>	<b>33 594</b>
<b>Current assets</b>		
Inventories	6 996	5 491
Trade and other receivables	74 820	71 608
Current corporate income tax	-	92
Treasury shares redeemed	4	4
Cash and cash equivalents	49	250
<b>Total current assets</b>	<b>81 869</b>	<b>77 445</b>
<b>Total assets</b>	<b>114 154</b>	<b>111 039</b>
<b>LIABILITIES</b>		
<b>Equity</b>		
Share capital	82 200	72 200
Reserves	11 800	10 601
Retained earnings	4 988	11 199
<b>Total</b>	<b>98 988</b>	<b>94 000</b>
<b>Non-current liabilities</b>		
Long-term loans	112	180
Deferred tax liabilities	1 264	1 264
Retirement benefit obligations	119	119
<b>Total non-current liabilities</b>	<b>1 495</b>	<b>1 563</b>
<b>Current liabilities</b>		
Trade and other liabilities	3 394	4 186
Short-term loans	9 786	9 785
Current portion of long-term loans	263	409
Current corporate income tax		217
Other tax liabilities	228	879
<b>Total current liabilities</b>	<b>13 671</b>	<b>15 476</b>
<b>Total liabilities</b>	<b>15 166</b>	<b>17 039</b>
<b>Total equity and liabilities</b>	<b>114 154</b>	<b>111 039</b>

Date of preparation: 25.07.2019

Sofia

Prepared by:.....

/P. Moneva/

Executive Director:.....

/B. Georgiev/



**Tchaikapharma High Quality Medicines Inc.**  
**Interim statement of comprehensive income**  
**as of 30 of June 2019**

	<b>30.06.2019</b>	<b>30.06.2018</b>
	<b>BGN'000</b>	<b>BGN'000</b>
Revenue	18 825	18 509
Other income	1	10
<b>Total income</b>	<b>18 826</b>	<b>18 519</b>
Carrying amount of goods sold	(584)	(1 264)
Changes in inventories of finished products and work in progress	1 325	(59)
Materials and services	(9 903)	(8 045)
Personnel expenses	(2 002)	(1 807)
Depreciation / amortisation expenses	(1 907)	(1 669)
Other expenses	(423)	(132)
Finance income	8	6
Finance costs	(168)	(158)
<b>Total expenses</b>	<b>(13 654)</b>	<b>(13 128)</b>
<b>Profit before taxation</b>	<b>5 172</b>	<b>5 391</b>
Corporate income tax expense	(184)	(492)
<b>Profit/Loss for the period</b>	<b>4 988</b>	<b>4 899</b>

**Total comprehensive income for the period**

Earnings per share / in BGN per 1 share /	0.06	0.07
---	------	------

Date of preparation: 25.07.2019

Sofia

Prepared by:..... Executive Director:.....

/ P. Moneva /

/B. Georgiev/



**Tchaikapharma High Quality Medicines Inc.**  
**Interim cash flow statement**  
**as of 30 of June 2019**

	<b>30.06.2019</b>	<b>30.06.2018</b>
	<i>BGN'000</i>	<i>BGN'000</i>
<b>Cash flows from operating activities</b>		
Proceeds from sale of finished products, goods and services	16 458	13 280
Payments to suppliers of materials, goods and services	(9 343)	(6 635)
Payments to personnel	(1 846)	(1 674)
Payments of interest and dividends	(315)	(571)
Other proceeds / payments	(4 176)	(3 252)
<b><i>Net cash flows</i></b>	<b>778</b>	<b>1 148</b>
<b>Cash flows from investing activities</b>		
Payments on non-current assets acquired	(634)	(773)
<b><i>Net cash flows</i></b>	<b>(634)</b>	<b>(773)</b>
<b>Cash flows from financial activities</b>		
Proceeds from loans	99	2
Payments on loans	(197)	1
Payment of interest, dividends	(22)	(98)
Payments on finance lease	(225)	(296)
<b><i>Net cash flows</i></b>	<b>(345)</b>	<b>(364)</b>
<b>Change in cash and cash equivalents</b>	<b>(201)</b>	<b>11</b>
Cash and cash equivalents at the beginning of the period	250	24
Cash and cash equivalents at the end of the period	49	35

Date of preparation: 25.07.2019

Sofia

Prepared by:.....

/ P. Moneva

Executive

Director:.....

/B. Georgiev /



**Tchaikapharma High Quality Medicines Inc.**  
**Interim statement on changes in equity**  
**as of 30 of June 2019**

	Registered (share) capital <i>BGN'000</i>	Revaluation reserves <i>BGN'000</i>	Other reserves <i>BGN'000</i>	Retained earnings / loss <i>BGN'000</i>	Total equity <i>BGN'000</i>
<b>Balance as of 01.01.2018</b>	<b>63 400</b>	<b>3 626</b>	<b>5 546</b>	<b>8 831</b>	<b>82 303</b>
Profit/loss for the period				11 199	11 199
Other comprehensive income		498			498
Including from tax effect of the revaluation of property, plant and equipment		(72)			(72)
<b>Total comprehensive income</b>		<b>498</b>		<b>11 199</b>	<b>11 697</b>
Issue of shares by the owners	7 900			(7 900)	
Dividends accrued					
Tantiemmes accrued					
Profit transferred to reserves			931	(931)	
<b>Total amount of income and expenses recognised during the period</b>	<b>7 900</b>		<b>931</b>	<b>(8 831)</b>	
<b>Balance as of 31.12.2018</b>	<b>72 200</b>	<b>4 124</b>	<b>6 477</b>	<b>11 199</b>	<b>94 000</b>
<b>Balance as of 01.01.2019</b>	<b>72 200</b>	<b>4 124</b>	<b>6 477</b>	<b>11 199</b>	<b>94 000</b>
Profit/loss for the period				4 988	4 988
Other comprehensive income					
<b>Total comprehensive income</b>				<b>4 988</b>	<b>4 988</b>
Issue of shares by the owners	10 000			(10 000)	
Dividends accrued					
Tantiemmes accrued					
Profit transferred to reserves		79	1 120	(1 199)	
<b>Total amount of income and expenses recognised during the period</b>	<b>10 000</b>	<b>79</b>	<b>1 120</b>	<b>(11 199)</b>	
<b>Balance as of 30.06.2019</b>	<b>82 200</b>	<b>4 203</b>	<b>7 597</b>	<b>4 988</b>	<b>98 988</b>

Date of preparation: 25.07.2019  
Sofia

Prepared by:.....

/P. Moneva/

Executive Director:.....

/B. Georgiev /

